Rare Disease Landscape: Why You Need a Different Launch Playbook (VIDEO)
This excerpt from our Pharmaceutical Executive presentation shares the challenges and growth in the landscape of rare diseases, with about 7,000 identified but only 5% having treatments. This affects 30 million people in the US, including 16 million children, with 41% misdiagnosed and long diagnosis timelines.
Over half of recent drug approvals are for orphan drugs, leading to a growing revenue share despite the challenges of small patient populations and high costs. Most approvals utilize expedited pathways, increasing competition and pressuring companies to be first to market or demonstrate differentiation.
Other Rare Disease Resources:
Rare Disease Landscape: What we heard from CCOs (VIDEO)
In this video, we explore the evolving landscape of rare diseases, highlighting patients’ diagnostic and treatment challenges, as well as competitive dynamics and tailored launch strategies.
Identify Rare Disease Product Launch Archetypes
Learn how to identify your rare disease product launch archetype to optimize your launch planning.
